{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T00:16:16Z","timestamp":1795047376126,"version":"4.10.2"},"reference-count":40,"publisher":"Begell House","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Eukaryot Gene Expr"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>Prostate cancer (PRAD) progression varies significantly among patients, with metabolic reprogramming linked to oncogenesis and immune response. However, the prognostic and immune-related roles of metabolic reprogramming-related genes (MRGs) in PRAD remain unclear. PRAD transcriptomic, mutation, and clinical data from TCGA were analyzed. WGCNA identified PRAD-associated gene modules. NMF clustering stratified patients into two molecular subgroups. Prognostic MRGs were screened via univariate Cox and LASSO regression. A gene-based prognostic model was established and validated using ROC, PCA, and Kaplan-Meier analyses. A clinical-variable nomogram predicted survival, with external validation via GEO data set GSE70770. Immune traits of subtypes\/risk groups were assessed via ESTIMATE, CIBERSORT, and ssGSEA. Drug sensitivity and gene expression (qRT-PCR) were evaluated. Two metabolic subtypes with distinct survival and immune patterns were identified. A four-gene signature (AKR1C2, PITPNM3, PLA2G5, UCK2) formed a prognostic model. Risk stratification revealed groups with divergent survival rates. High-risk patients exhibited poorer outcomes, reduced immune infiltration, and altered drug sensitivity. The MRG prognostic model stratifies PRAD patients by survival and immune landscape, aiding precision immunotherapy and drug discovery.<\/p>","DOI":"10.1615\/critreveukaryotgeneexpr.2025060696","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T18:30:41Z","timestamp":1753813841000},"page":"11-25","source":"Crossref","is-referenced-by-count":1,"title":["Identification of Novel Molecular Subtypes of Prostate Cancer Based on Genes Related to Metabolic Reprogramming to Assess Prognosis and Immune Landscape"],"prefix":"10.1615","volume":"35","author":[{"given":"Wentao","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2024;74(3):229-63.","DOI":"10.3322\/caac.21834"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, Modi S, Bardia A, Tolaney SM, Cortes J, Soria JC, Curigliano G. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA: Cancer J Clin. 2022;72(2):165-82.","DOI":"10.3322\/caac.21705"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Graham LS, Lin JK, Lage DE, Kessler ER, Parikh RB, Morgans AK. Management of prostate cancer in older adults. Am Soc Clin Oncol Educ Book. 2023;43:e390396.","DOI":"10.1200\/EDBK_390396"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Iyengar S, Hall IJ, Sabatino SA. Racial\/ethnic disparities in prostate cancer incidence, distant stage diagnosis, and mortality by U.S. census region and age group, 2012-2015. Cancer Epidemiol, Biomarkers Prevent. 2020;29(7):1357-64.","DOI":"10.1158\/1055-9965.EPI-19-1344"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Rebbeck TR. Prostate cancer genetics: Variation by race, ethnicity, and geography. Sem Radiat Oncol. 2017;27(1):3-10.","DOI":"10.1016\/j.semradonc.2016.08.002"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: J Clin. 2021;71(3):209-49.","DOI":"10.3322\/caac.21660"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Chu F, Chen L, Guan Q, Chen Z, Ji Q, Ma Y, Ji J, Sun M, Huang T, Song H, Zhou H. Global burden of prostate cancer: Age-period-cohort analysis from 1990 to 2021 and projections until 2040. World J Surg Oncol. 2025;23(1):98.","DOI":"10.1186\/s12957-025-03733-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Wasim S, Lee SY, Kim J. Complexities of prostate cancer. Int J Mol Sci. 2022;23(22).","DOI":"10.3390\/ijms232214257"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Shoag J, Barbieri CE. Clinical variability and molecular heterogeneity in prostate cancer. Asian J Androl. 2016;18(4):543-8.","DOI":"10.4103\/1008-682X.178852"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Feng DC, Zhu WZ, Wang J, Li DX, Shi X, Xiong Q, You J, Han P, Qiu S, Wei Q, Yang L. The implications of single-cell RNA-seq analysis in prostate cancer: Unraveling tumor heterogeneity, therapeutic implications and pathways towards personalized therapy. Military Med Res. 2024;11(1):21.","DOI":"10.1186\/s40779-024-00526-7"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Hanahan D. Hallmarks of cancer: New dimensions. Cancer Discov. 2022;12(1):31-46.","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Martinez-Reyes I, Chandel NS. Cancer metabolism: Looking forward. Nature Rev Cancer. 2021;21(10):669-80.","DOI":"10.1038\/s41568-021-00378-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Jiang M, Fang H, Tian H. Metabolism of cancer cells and immune cells in the initiation, progression, and metastasis of cancer. Theranostics. 2025;15(1):155-88.","DOI":"10.7150\/thno.103376"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Foo BJ, Eu JQ, Hirpara JL, Pervaiz S. Interplay between mitochondrial metabolism and cellular redox state dictates cancer cell survival. Oxid Med Cell Longev. 2021;2021:1341604.","DOI":"10.1155\/2021\/1341604"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z. Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers. Cell Rep. 2018;23(1):255-69.","DOI":"10.1016\/j.celrep.2018.03.077"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E. The immune landscape of cancer. Immunity. 2018;48(4):812-30.","DOI":"10.1016\/j.immuni.2018.03.023"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Li S, Chen J, Chen X, Yu J, Guo Y, Li M, Pu X. Therapeutic and prognostic potential of GPCRs in prostate cancer from multi-omics landscape. Front Pharmacol. 2022;13:997664.","DOI":"10.3389\/fphar.2022.997664"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Menendez JA, Alarc\u00f3n T. Metabostemness: A new cancer hallmark. Front Oncol. 2014;4:262.","DOI":"10.3389\/fonc.2014.00262"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Beier AK, Puhr M, Stope MB, Thomas C, Erb HHH. Metabolic changes during prostate cancer development and progression. J Cancer Res Clin Oncol. 2023;149(5):2259-70.","DOI":"10.1007\/s00432-022-04371-w"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Yang B, Jiang Y, Yang J, Zhou W, Yang T, Zhang R, Xu J, Guo H. Characterization of metabolism-associated molecular patterns in prostate cancer. BMC Urol. 2023;23(1):104.","DOI":"10.1186\/s12894-023-01275-w"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Ji Q, Chang L, Stanczyk FZ, Ookhtens M, Sherrod A, Stolz A. Impaired dihydrotestosterone catabolism in human prostate cancer: Critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res. 2007;67(3):1361-9.","DOI":"10.1158\/0008-5472.CAN-06-1593"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Huang KH, Chiou SH, Chow KC, Lin TY, Chang HW, Chiang IP, Lee MC. Overexpression of aldo-keto reductase 1C2 is associated with disease progression in patients with prostatic cancer. Histopathology. 2010;57(3):384-94.","DOI":"10.1111\/j.1365-2559.2010.03647.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Wang Z, Feng Y, Song J, Sun D, Zhang YY. Function, drug resistance and prognostic effect of AKR1C2 in human cancer. Neoplasma. 2023;70(3):319-32.","DOI":"10.4149\/neo_2023_230206N66"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Grabon A, Khan D, Bankaitis VA. Phosphatidylinositol transfer proteins and instructive regulation of lipid kinase biology. Biochim Biophys Acta. 2015;1851(6):724-35.","DOI":"10.1016\/j.bbalip.2014.12.011"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Wyckoff GJ, Solidar A, Yoden MD. Phosphatidylinositol transfer proteins: Sequence motifs in structural and evolutionary analyses. J Biomed Sci Eng. 2010;3(1):65-77.","DOI":"10.4236\/jbise.2010.31010"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Hong R, Shen MH, Xie XH, Ruan SM. Inhibition of breast cancer metastasis via PITPNM3 by pachymic acid. Asian Pac J Cancer Prev. 2012;13(5):1877-80.","DOI":"10.7314\/APJCP.2012.13.5.1877"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Yang B, Jiao Z, Feng N, Zhang Y, Wang S. Long non-coding RNA MIR600HG as a ceRNA inhibits the pancreatic cancer progression through regulating the miR-1197\/PITPNM3 axis. Heliyon. 2024;10(2):e24546.","DOI":"10.1016\/j.heliyon.2024.e24546"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Murakami M. Lipoquality control by phospholipase A(2) enzymes. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(9):677-702.","DOI":"10.2183\/pjab.93.043"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Hidalgo I, Sorolla MA, Sorolla A, Salud A, Parisi E. Secreted phospholipases A2: Drivers of inflammation and cancer. Int J Mol Sci. 2024;25(22).","DOI":"10.3390\/ijms252212408"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Wu C, Su J, Wang X, Wang J, Xiao K, Li Y, Xiao Q, Ling M, Xiao Y, Qin C, Long W. Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis. Cancer Manage Res. 2019:3139-52.","DOI":"10.2147\/CMAR.S199207"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Vecchi L, Araujo TG, Azevedo FV, Mota ST, Avila VD, Ribeiro MA, Goulart LR. Phospholipase A2 drives tumorigenesis and cancer aggressiveness through its interaction with annexin A1. Cells. 2021;10(6):1472.","DOI":"10.3390\/cells10061472"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Fu Y, Wei XD, Guo L, Wu K, Le J, Ma Y, Kong X, Tong Y, Wu H. The metabolic and non-metabolic roles of UCK2 in tumor progression. Front Oncol. 2022;12: 904887.","DOI":"10.3389\/fonc.2022.904887"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Wu X, Chen D, Li M, Liang G, Ye H. UCK2 promotes intrahepatic cholangiocarcinoma progression and desensitizes cisplatin treatment by PI3K\/AKT\/mTOR\/autophagic axis. Cell Death Discov. 2024;10(1):375.","DOI":"10.1038\/s41420-024-02140-x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Yu Y, You S, Fan R, Shan X. UCK2 regulated by miR-139-3p regulates the progression of hepatocellular carcinoma cells. Future Oncol. 2022;18(8):979-90.","DOI":"10.2217\/fon-2021-0271"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Zhou Q, Jiang H, Zhang J, Yu W, Zhou Z, Huang P, Wang J, Xiao Z. Uridine-cytidine kinase 2 promotes metastasis of hepatocellular carcinoma cells via the Stat3 pathway. Cancer Manage Res. 2018 Nov 26:6339-55.","DOI":"10.2147\/CMAR.S182859"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Wu Y, Jamal M, Xie T, Sun J, Song T, Yin Q, Li J, Pan S, Zeng X, Xie S, Zhang Q. Uridine-cytidine kinase 2 (UCK 2): A potential diagnostic and prognostic biomarker for lung cancer. Cancer Sci. 2019;110(9):2734-47.","DOI":"10.1111\/cas.14125"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature Med. 2013;19(11):1423-37.","DOI":"10.1038\/nm.3394"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Stower H. Revising salt consumption. Nature Med. 2018;24(9):1303.","DOI":"10.1038\/s41591-018-0193-5"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Pu K, Gao J, Feng Y, Hu J, Tang S, Yang G, Xu C. Comprehensive evaluation of immunological attributes and immunotherapy responses of positive T cell function regulators in colorectal cancer. BMC Gastroenterol. 2024;24(1):339.","DOI":"10.1186\/s12876-024-03409-2"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Pan H, Pan J, Li P, Wu J. Immunologic gene sets reveal features of the tumor immune microenvironment and predict prognosis and immunotherapy response: A pan-cancer analysis. Front Immunol. 2022;13:858246.","DOI":"10.3389\/fimmu.2022.858246"}],"container-title":["Critical Reviews in Eukaryotic Gene Expression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/1bb57e331a4748bf\/CRE-60696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:25:37Z","timestamp":1761283537000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/6dbf508d3b17c437,6b924d6f5521c33e,1bb57e331a4748bf.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/critreveukaryotgeneexpr.2025060696","relation":{},"ISSN":["1045-4403"],"issn-type":[{"value":"1045-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}